


E KW 6002/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 155270-99-8 REGISTRY
ED Entered STN: 24 May 1994
CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-
3,7-dihydro-7-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-, (E)-
OTHER NAMES:
CN Istradefylline
CN KW 6002
FS STEREOSEARCH
MF C20 H24 N4 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA,
CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH,
IPA, MEDLINE, MRCK*, PROMT, PROUSDDR, RTECS*, SYNTHLINE, TOXCENTER,
USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



SET EXPAND CONTINUOUS
L1 1 S E3

FILE 'HCAPLUS' ENTERED AT 14:21:41 ON 20 APR 2010
L2 113 S L1
L3 3 S L2 AND (COGNITION OR COGNITIVE)
L4 0 S L3 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

FILE 'HCAPLUS' ENTERED AT 14:22:38 ON 20 APR 2010
L5 1 S US 20070078148/PN
L6 2 S L1 AND MEMORY, BIOLOGICAL/IT
L7 54 S L2 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L8 1 S L6 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Xanthine derivatives and salts and compositions for preventing and/or

treating higher brain dysfunction

AB A preventive and/or therapeutic agent for higher brain dysfunctions which contains as an active ingredient a xanthine derivative represented, for example, by the following formula (I) or a pharmacol. acceptable salt thereof: (I) (II) wherein R1, R2, and R3 are the same or different and each represents hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R4 represents cycloalkyl, -(CH2)n-R5, or the formula (II) given above; and X1 and X2 are the same or different and each represents oxygen or sulfur. The higher brain dysfunction includes aging brain damage, brain trauma, cerebrovascular disease, memory disorder, thinking disorder, recognition disorder, behavior disorder, learning disorder, etc.

ACCESSION NUMBER: 2005:547543 HCAPLUS Full-text

DOCUMENT NUMBER: 143:53542

TITLE: Xanthine derivatives and salts and compositions for

preventing and/or treating higher brain

dysfunction

INVENTOR(S): Kase, Hiroshi; Nakagawa, Yutaka; Shiozaki, Shizuo;

Kobayashi, Minoru; Toki, Shinichiro; Seno,

Naoki;

Ikeda, Ken

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2005056016	A1	20050623	WO 2004-JP18765	
20041209 <--				
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,				
CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,				
GB, GD,				
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,				
KZ, LC,				
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,				
NA, NI,				
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,				
SL, SY,				
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,				
ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,				
ZW, AM,				
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,				
DE, DK,				
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,				
PL, PT,				

RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML,

MR, NE, SN, TD, TG

AU 2004296137 A1 20050623 AU 2004-296137

20041209 <--

CA 2550130 A1 20050623 CA 2004-2550130

20041209 <--

EP 1709966 A1 20061011 EP 2004-807124

20041209 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,

IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

CN 1889959 A 20070103 CN 2004-80036267

20041209 <--

BR 2004017241 A 20070306 BR 2004-17241

20041209 <--

US 20070078148 A1 20070405 US 2006-579829

20060517 <--

MX 2006005965 A 20060809 MX 2006-5965

20060525 <--

KR 2006124615 A 20061205 KR 2006-711123

20060607 <--

ZA 2006004723 A 20091125 ZA 2006-4723

20060608 <--

IN 2006CN02490 A 20070608 IN 2006-CN2490

20060706 <--

PRIORITY APPLN. INFO.: JP 2003-410432 A

20031209 <--

WO 2004-JP18765 W

20041209

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:53542

IC ICM A61K031-522

ICS A61P025-28; C07D473-12; C07D473-06

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

IT Behavior

Memory, biological

(recognition; xanthine derivs. and salts and compns. for
preventing

and/or treating higher brain dysfunction)

IT 51-34-3, Scopolamine 69-89-6D, Xanthine, derivs. and salts
51389-37-8

141807-96-7 155270-99-8 155272-00-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(xanthine derivs. and salts and compns. for preventing and/or

treating

higher brain dysfunction)

L9 3 S L1 AND MEMORY

L10 1 S L9 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L11 0 S L10 NOT L8

L12 1 S L1 AND LEARNING DISORDERS/IT

L13 0 S L12 NOT L8

L14 5 S L1 AND BRAIN, DISEASE/IT

L15 3 S L14 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)

L16 2 S L15 NOT L8
 L17 5 S L1 AND TRAUMA?
 L18 2 S L17 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
 L19 1 S L18 NOT L8

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2010 ACS on STN

TI A method using an adenosine A2A receptor antagonist for treating
 an anxiety disorder

AB Anxiety disorders, such as panic disorder, agoraphobia, obsessive-
 compulsive disorder, social phobia, post-traumatic stress
 disorder, generalized anxiety disorder, specific phobia, or the
 like, are treated by administering an effective amount of at least
 one adenosine A2A receptor antagonist (e.g. a xanthine derivative)
 to a patient in need thereof, optionally in combination with an
 anxiolytic(s) other than the adenosine A2A receptor antagonist.

ACCESSION NUMBER: 2004:1080800 HCAPLUS Full-text

DOCUMENT NUMBER: 142:33005

TITLE: A method using an adenosine A2A receptor
 antagonist

INVENTOR(S): for treating an anxiety disorder
 Kase, Hiroshi; Seno, Naoki; Shiozaki, Shizuo;
 Kobayashi, Minoru; Kase, Junya

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108137	A1	20041216	WO 2004-JP8486	
20040610 <--				
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,			
CA, CH,	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,			
GB, GD,	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,			
KZ, LC,	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,			
NA, NI,	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,			
SL, SY,	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,			
ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,			
ZW, AM,	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,			
DE, DK,	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT,			
RO, SE,	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,			
MR, NE,	SN, TD, TG			

AU 2004244906	A1	20041216	AU 2004-244906
20040610 <--			
CA 2528710	A1	20041216	CA 2004-2528710
20040610 <--			
EP 1631294	A1	20060308	EP 2004-746014
20040610 <--			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1787821	A	20060614	CN 2004-80012845
20040610 <--			
BR 2004011120	A	20060718	BR 2004-11120
20040610 <--			
JP 2006527264	T	20061130	JP 2006-516839
20040610 <--			
US 20060281770	A1	20061214	US 2005-553250
20051017 <--			
KR 2006037252	A	20060503	KR 2005-721878
20051116 <--			
MX 2005013148	A	20060317	MX 2005-13148
20051205 <--			
NO 2005005907	A	20051213	NO 2005-5907
20051213 <--			
IN 2006CN00077	A	20070629	IN 2006-CN77
20060106 <--			
PRIORITY APPLN. INFO.:			US 2003-509046P P
20030610 <--			US 2003-532793P P
20031224 <--			WO 2004-JP8486 W

20040610

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:33005

IC ICM A61K031-522
ICS A61K031-519; A61P025-22
CC 1-11 (Pharmacology)
IT Mental and behavioral disorders
(post-traumatic stress disorder; adenosine A2A receptor antagonist for treating anxiety disorders)
IT 69-89-6D, Xanthine, derivs. 51389-37-8 99331-25-6D, Triazolopyrimidine, derivs. 155270-99-8 262452-04-0 377727-87-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonist for treating anxiety disorders)

L20	7 S L1 AND IMPAIR?
L21	2 S L20 AND (PY<=2003 OR AY<=2003 OR PRY<=2003)
L22	2 S L21 NOT L8
L23	2 S L22 NOT L19